Ensartinib
First- and later-line treatment of ALK-positive non-small cell lung cancer
- CAS No.
- 1370651-20-9
- Indication Class
- Oncology / Hematology
- Patent Expiry
- To be assessed
- Therapeutic Area
- Oncology / Lung Cancer
- Target / Mechanism
- ALK
- Labeled Purity
- 98%+
- Registration Readiness
- —
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A China-originated ALK inhibitor with globally competitive efficacy and safety, a mature asset for domestic innovative-drug export and licensing.
Oncology / Lung Cancer · Marketed; available for immediate sourcing
—-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Data File Pack
Product Description
Ensartinib is an oral tyrosine kinase inhibitor primarily used for the treatment of ALK positive non-small cell lung cancer (NSCLC).
Supply source: Unibest · Ensartinib, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.